Cancer patients lose out in NHS overspend
January 6, 2014Research and Development, Sales and Marketing Cancer, Macmillan, NHS England
Patients in the NHS may not be able to receive new treatments for cancer as it emerges that health chiefs …
Aeterna Zentaris appoints former Boehringer head
January 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing aeterna zentaris
Speciality biopharma firm Aeterna Zentaris has hired Dr Richard Sachse to be its senior vice president and chief scientific officer. …
GSK sells off non-core assets
January 6, 2014Sales and Marketing GSK, Suntory, aspen, lucozade, ribena
GlaxoSmithKline has completed the offloading of several of its non-core assets in moves which stand to net the pharma manufacturer …
Regulate, don’t strangulate
January 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, code of practise, low, myeloma
As many of you will know, work is now under way to revise the ABPI Code. Not before time I …
China ban for corrupt pharma firms
January 2, 2014Medical Communications, Sales and Marketing Cameron, China, GSK, Witty, bribery, lilly
‘Printed’ eye cells could herald new treatments
December 24, 2013Research and Development, Sales and Marketing biofabrication, blind, blindness, eye printing
Researchers from Cambridge University have printed new eye cells using a standard printer that could herald new treatments to stop …
Symphogen hires non-executive director
December 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing symphogen
Sweden-based Biopharma firm Symphogen has appointed Annika Espander Jansson as a non-executive director to its board. Jansson has over 20 …
Boehringer launches psychiatric research project
December 23, 2013Research and Development, Sales and Marketing Boehringer, circuit, psychiatry
Boehringer Ingelheim has announced it will collaborate on a new three-year programme to investigate the neural foundations of psychiatric disorders. …
Thyroid cancer, TB resistance drugs top EMA approvals
December 23, 2013Sales and Marketing EMA, TB, thyroid
The European Medicines Agency has shown the green light to a new treatment for thyroid cancer and one for drug …
Board changes at Bayer
December 23, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, malik
Bayer has appointed Kemal Malik to its management board with responsibility for innovation, succeeding Wolfgang Plischke who is retiring. Bayer …
ABPI appoints Weber Shandwick for comms support
December 20, 2013Medical Communications, Sales and Marketing PR, Weber shandwick, apbi, comms, digital, luther
The Association of the British Pharmaceutical Industry has taken on Weber Shandwick to lead its public affairs and communications strategy. …
Wellcome Trust makes $100m from Twitter shares
December 20, 2013Medical Communications, Sales and Marketing Francis Crick Institute, Twitter, University College London, University of Cambridge, University of Oxford, Wellcome Trust
The Wellcome Trust has walked away with a profit of more than $100 million from a previously undisclosed investment in …
Merck, Reckitt Benckiser fined by French watchdog
December 20, 2013Manufacturing and Production, Sales and Marketing FCA, Merck, Reckitt Benckiser, generics, subutex
Merck & Co and Reckitt Benckiser have collectively been fined millions of euros by French authorities over their role in …
New managing director for UBM Live in Amsterdam
December 20, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ubm live, van der walk
Events-led marketing and comms firm UBM Live has appointed John van der Valk as the new managing director for its …
New chief executive for Gates Foundation
December 19, 2013Research and Development, Sales and Marketing Gates, Gates Foundation, Susan Desmond-Hellmann, uccsf
The Bill & Melinda Gates Foundation has picked Susan Desmond-Hellmann as its next chief executive. Desmond-Hellmann sits on the boards …
BMS sells diabetes stake to partner AstraZeneca
December 19, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze
AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …
Bayer in $2.9 billion Algeta deal
December 19, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer and Algeta have decided to avoid the usual M&A dance, opting instead to agree a business deal with little …
Pharma displaying ‘pathological lack of corporate integrity’
December 19, 2013BMJ, FDA, wolfe. pharma
The system that hands out financial penalties to drug companies for illegal activities is failing to deter companies from repeatedly …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
